{"id":71409,"date":"2026-05-20T09:18:16","date_gmt":"2026-05-20T09:18:16","guid":{"rendered":"https:\/\/medsbase.com\/l-carnitine\/"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"l-carnitine","status":"publish","type":"product","link":"https:\/\/medsbase.com\/es\/product\/l-carnitine\/","title":{"rendered":"L-Carnitina (Levocarnitina)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Respuesta r\u00e1pida \u2014 \u00bfQu\u00e9 es la L-Carnitina?<\/h3>\n<p style=\"margin: 0;\"><strong>L-Carnitina<\/strong> (levocarnitina; (3R)-3-hidroxi-4-(trimetilamonio)butanoato) es un peque\u00f1o derivado de amino\u00e1cido de amonio cuaternario \u2014 <em>no es un p\u00e9ptido<\/em> \u2014 that functions as the essential carrier molecule for transporting long-chain fatty acids across the mitochondrial inner membrane for \u03b2-oxidation. It is endogenously biosynthesised from L-lysine and L-methionine and is concentrated in skeletal muscle, heart, and liver. L-Carnitine is studied across mitochondrial-function studies, fat-oxidation physiology, insulin-sensitivity models, cardiovascular studies, neuroprotection (Alzheimer \/ autism in-vitro work), exercise physiology, and sperm-motility studies. Supplied in 600 mg and 1200 mg vials as levocarnitine USP-grade zwitterion for clinical studies use only. Stocked in our peptide catalogue alongside <a href=\"https:\/\/medsbase.com\/es\/nad\/\">NAD\u207a<\/a> as a complementary mitochondrial \/ metabolic support-injectable.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Qu\u00e9 obtienes con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/es\/reviews\/\">opiniones de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada pedido est\u00e1 cubierto por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 si tu paquete no llega en 20 d\u00edas laborables, lo reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especificaci\u00f3n<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalle<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">541-15-1 (sal interna de L-carnitina \/ zwitteri\u00f3n)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Derivado de amino\u00e1cido de amonio cuaternario (<em>no es un p\u00e9ptido<\/em>); el enanti\u00f3mero lev\u00f3giro (3R) es la forma biol\u00f3gicamente activa responsable del transporte mitocondrial de \u00e1cidos grasos de cadena larga a trav\u00e9s del sistema carnitina palmitoiltransferasa (CPT-I \/ CPT-II); biosintetizado end\u00f3genamente a partir de L-lisina y L-metionina; tambi\u00e9n llamado levocarnitina (DCI) o Vitamina B<sub>T<\/sub> en literatura antigua<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>7<\/sub>H<sub>15<\/sub>NO<sub>3<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">161,20 g\/mol<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nombre IUPAC<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">(3R)-3-Hidroxi-4-(trimetilazaniumil)butanoato<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Secuencia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">n\/a (derivado de amino\u00e1cido de peque\u00f1a mol\u00e9cula \u2014 no es un p\u00e9ptido)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Polvo liofilizado, blanco a blanquecino (forma zwitteri\u00f3n \/ sal interna)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA bajo solicitud)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Almacenamiento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (refrigerador) para stock de trabajo a corto plazo; \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Reconstituido: 2\u20138 \u00b0C, usar en ~30 d\u00edas. Proteger de la luz. Evitar ciclos repetidos de congelaci\u00f3n-descongelaci\u00f3n de la soluci\u00f3n reconstituida. La levocarnitina es higrosc\u00f3pica \u2014 cerrar los viales inmediatamente despu\u00e9s de cada extracci\u00f3n.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidad<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Muy soluble en agua (zwitteri\u00f3n a pH fisiol\u00f3gico). Se reconstituye r\u00e1pidamente en agua bacteriost\u00e1tica o agua est\u00e9ril con agitaci\u00f3n suave. No se requieren disolventes especializados. Las soluciones de trabajo pueden prepararse a concentraciones de hasta ~500 mg\/mL sin precipitaci\u00f3n.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00bfQu\u00e9 es la L-Carnitina?<\/h2>\n<p><strong>L-Carnitina<\/strong> (levocarnitina) es un derivado de amino\u00e1cido de amonio cuaternario, peque\u00f1o y soluble en agua, con la f\u00f3rmula molecular C<sub>7<\/sub>H<sub>15<\/sub>NO<sub>3<\/sub> y peso molecular 161,20 g\/mol. Es <em>no es un p\u00e9ptido<\/em> \u2014 it is a single-residue zwitterionic molecule derived metabolically from the amino acids L-lysine and L-methionine through a multistep biosynthetic pathway distributed across kidney, liver, and brain. Only the (3R) enantiomer (the L-form \/ levo form \/ levocarnitine) is biologically active; the (3S) enantiomer (D-carnitine) is inactive and is now well-documented to interfere with the L-form&#8217;s transport, which is why pharmaceutical-grade material is supplied as the enantiomerically pure L-form rather than as racemic DL-carnitine. The molecule&#8217;s central physiological function is to serve as the <strong>transportador obligado<\/strong> para transportar \u00e1cidos grasos de cadena larga (C<sub>12<\/sub>+) across the otherwise-impermeable mitochondrial inner membrane, where they are subsequently broken down by \u03b2-oxidation to acetyl-CoA, the substrate for the citric acid cycle and ATP synthesis. The transport machinery \u2014 carnitine palmitoyltransferase I (CPT-I) on the outer mitochondrial membrane, the carnitine\/acylcarnitine translocase (CACT) across the inner membrane, and carnitine palmitoyltransferase II (CPT-II) on the matrix side \u2014 converts free fatty acids into acylcarnitines, ferries them across the bilayer, and releases them again as acyl-CoAs for oxidation. L-Carnitine is therefore the rate-limiting metabolite for fat oxidation in tissues with high oxidative demand: skeletal muscle, cardiac muscle, and liver. L-Carnitine is also a high-affinity buffer of the cellular acyl-CoA \/ free-CoA ratio. By accepting acyl groups onto its hydroxyl side chain, L-carnitine maintains the intracellular pool of free CoA that other CoA-dependent enzymes (pyruvate dehydrogenase, \u03b1-ketoglutarate dehydrogenase, fatty-acid \u03b2-oxidation) require to function. Carnitine deficiency therefore produces effects beyond fat oxidation alone \u2014 propagating into pyruvate handling, TCA-cycle flux, and overall mitochondrial bioenergetic balance. L-Carnitine has FDA approval (under the name <em>levocarnitina<\/em>) para uso terap\u00e9utico humano en <strong>deficiencia primaria y secundaria de carnitina<\/strong> (oral and IV formulations) and is widely used in contexts that examine mitochondrial bioenergetics, fat oxidation, insulin sensitivity, cardiovascular function, neuroprotection, exercise physiology, and sperm motility. <\/p>\n<h2>Mecanismo de acci\u00f3n \u2014 Transporte mitocondrial de \u00e1cidos grasos de cadena larga<\/h2>\n<p>L-Carnitine&#8217;s central mechanism is documented across several decades of mitochondrial biochemistry studies:<\/p>\n<ul>\n<li><strong>Carnitina palmitoiltransferasa I (CPT-I) \u2014 membrana mitocondrial externa<\/strong> \u2014 Los \u00e1cidos grasos de cadena larga primero se activan a acil-CoA de cadena larga en el citoplasma. La CPT-I, incrustada en la membrana mitocondrial externa, transfiere el grupo acilo de la CoA al hidroxilo de la L-carnitina, generando acilcarnitina de cadena larga. Este es el paso comprometido y m\u00e1s regulado de la oxidaci\u00f3n mitocondrial de grasas \u2014 la CPT-I es inhibida alost\u00e9ricamente por el malonil-CoA (el producto de la acetil-CoA carboxilasa en el metabolismo lipog\u00e9nico en estado de alimentaci\u00f3n), que es c\u00f3mo la insulina \/ glucag\u00f3n y el sistema AMPK regulan la oxidaci\u00f3n de grasas frente a la s\u00edntesis de grasas.<\/li>\n<li><strong>Carnitina\/acilcarnitina translocasa (CACT) \u2014 membrana mitocondrial interna<\/strong> \u2014 La acilcarnitina de cadena larga generada por la CPT-I no puede difundirse a trav\u00e9s de la membrana mitocondrial interna. La CACT, un antiportador, intercambia la acilcarnitina citos\u00f3lica por carnitina libre en la matriz en una estequiometr\u00eda 1:1, entregando acilcarnitina a la matriz y reciclando carnitina para m\u00e1s rondas de CPT-I.<\/li>\n<li><strong>Carnitina palmitoiltransferasa II (CPT-II) \u2014 membrana mitocondrial interna, orientada a la matriz<\/strong> \u2014 En la matriz, la CPT-II revierte la reacci\u00f3n de la CPT-I: transfiere el grupo acilo de la carnitina de nuevo a la CoA de la matriz, regenerando acil-CoA de cadena larga, que ahora puede entrar en la \u03b2-oxidaci\u00f3n. La carnitina libre liberada se devuelve a trav\u00e9s de la membrana mediante la CACT para otro ciclo de transporte.<\/li>\n<li><strong>Amortiguamiento de la relaci\u00f3n acil-CoA \/ CoA libre y flexibilidad metab\u00f3lica<\/strong> \u2014 M\u00e1s all\u00e1 del transporte de cadena larga, la L-carnitina acepta grupos acilo de cadena corta y media (acetilcarnitina, propionilcarnitina) y act\u00faa como un amortiguador de alta capacidad de la relaci\u00f3n acil-CoA \/ CoA libre intracelular. Esto mantiene la CoA libre para la piruvato deshidrogenasa, la \u03b1-cetoglutarato deshidrogenasa y la \u03b2-oxidaci\u00f3n. La generaci\u00f3n de acetilcarnitina tambi\u00e9n sirve como el mecanismo por el cual el exceso de acetil-CoA \u2014 proveniente del ayuno, la cetog\u00e9nesis, el ejercicio \u2014 puede amortiguarse de manera segura y exportarse a trav\u00e9s de la membrana mitocondrial.<\/li>\n<\/ul>\n<p>The pharmacokinetic profile of orally-administered L-carnitine is unusual: oral bioavailability is low (~15%) due to active intestinal saturation, with the remaining 85% subject to extensive bacterial degradation in the colon (yielding TMA and TMAO \u2014 a finding that has attracted attention in cardiovascular studies). Intravenous and intramuscular administration routes achieve much higher plasma levels and bypass the gut-microbial degradation pathway entirely, which is why pharmacological protocols commonly use parenteral administration despite the convenience of oral dosing. <\/p>\n<h2>Published Evidence<\/h2>\n<p>L-Carnitine is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Funci\u00f3n mitocondrial y bioenerg\u00e9tica<\/strong> \u2014 Respirometr\u00eda Seahorse \/ Oroboros, potencial de membrana mitocondrial, tasa de generaci\u00f3n de ATP, tasa de oxidaci\u00f3n de \u00e1cidos grasos en cultivos de hepatocitos primarios, m\u00fasculo esquel\u00e9tico y cardiomiocitos<\/li>\n<li><strong>Oxidaci\u00f3n de grasas y flexibilidad metab\u00f3lica<\/strong> \u2014 cambio entre la oxidaci\u00f3n de glucosa y grasas en el m\u00fasculo esquel\u00e9tico y el h\u00edgado; modelos de reversi\u00f3n de resistencia a la insulina; cohortes de estudio de roedores obesos y DIO<\/li>\n<li><strong>Insulin sensitivity studies<\/strong> \u2014 improvement in skeletal-muscle insulin sensitivity in models of metabolic syndrome and type 2 diabetes preclinical studies; mechanistic dissection of the L-carnitine \/ acyl-CoA buffering \/ pyruvate handling axis<\/li>\n<li><strong>Cardiovascular studies<\/strong> \u2014 angina, heart failure, ischemia-reperfusion injury, cardiomyopathy (in particular doxorubicin-induced cardiotoxicity and primary carnitine-deficiency cardiomyopathy); TMA\/TMAO microbiome-axis cardiovascular studies<\/li>\n<li><strong>Neuroprotection studies<\/strong> \u2014 Alzheimer-disease in-vitro models (acetylcarnitine specifically), Parkinson-disease models, peripheral diabetic neuropathy preclinical models, autism-spectrum studies where carnitine deficiency has been implicated<\/li>\n<li><strong>Sperm motility and male fertility studies<\/strong> \u2014 epididymal acquisition of motility, mitochondrial energetics of sperm flagellar beat, antioxidant protection of spermatozoa; one of the most-studied compounds in male-fertility studies<\/li>\n<li><strong>Exercise physiology and endurance studies<\/strong> \u2014 substrate utilisation during prolonged exercise, glycogen sparing, post-exercise recovery; studies interest in carnitine loading protocols and insulin co-administration to overcome muscle-uptake saturation<\/li>\n<li><strong>Chronic kidney disease \/ haemodialysis studies<\/strong> \u2014 carnitine deficiency is common in dialysis-dependent end-stage renal disease patients and L-carnitine has FDA approval for this indication; preclinical studies continues on dialysis-related cardiomyopathy and muscle weakness<\/li>\n<\/ul>\n<p>For broader context on mitochondrial and metabolic-axis compounds in this catalogue, see <a href=\"https:\/\/medsbase.com\/es\/nad\/\">NAD\u207a<\/a> (coenzima dinucle\u00f3tido oxidada, sustrato central de transporte de electrones), <a href=\"https:\/\/medsbase.com\/es\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> (p\u00e9ptido dirigido a mitocondrias que se une a cardiolipina), y <a href=\"https:\/\/medsbase.com\/es\/mots-c\/\">MOTS-c<\/a> (p\u00e9ptido regulador metab\u00f3lico derivado de mitocondrias). Explore el cat\u00e1logo completo <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">peptides &amp; compounds catalog<\/a> para compuestos relacionados. <\/p>\n<h2>Concentraciones y potencias disponibles<\/h2>\n<p>MedsBase stocks L-Carnitine in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Potencia del vial<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tama\u00f1os de paquete<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>600 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 dose-titration protocols, in-vitro mitochondrial-function panels, short-cycle in-vivo work, sperm-motility studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>1200 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle or higher-dose protocols \u2014 long-arm metabolic studies, exercise-physiology saturation experiments, multi-cohort work; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized levocarnitine zwitterion, \u226599% HPLC purity). Vial doses are deliberately much larger than the peptide range (5\u201320 mg) because L-carnitine is a small molecule used at gram-level doses \u2014 a 600 mg or 1200 mg vial corresponds roughly to a single intravenous dose in rodent or large-animal protocols. Users should determine specific dose ranges from peer-reviewed literature appropriate to the protocol. <\/p>\n<h2>C\u00f3mo se compara \u2014 L-Carnitina vs NAD\u207a<\/h2>\n<p>L-Carnitina y <a href=\"https:\/\/medsbase.com\/es\/nad\/\">NAD\u207a<\/a> are the two non-peptide mitochondrial \/ metabolic support compounds in this catalogue, and they target completely different layers of mitochondrial bioenergetics. L-Carnitine sits on the <em>lado del combustible<\/em> \u2014 transporta \u00e1cidos grasos de cadena larga hacia la matriz para la \u03b2-oxidaci\u00f3n. El NAD\u207a se sit\u00faa en el <em>lado del transporte de electrones<\/em> \u2014 it is the obligate electron acceptor for \u03b2-oxidation, glycolysis, and the TCA cycle, regenerated by Complex I of the electron transport chain. The two compounds are mechanistically complementary, and protocols sometimes combine them to probe upstream-substrate vs downstream-electron-flux contributions to mitochondrial output. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">L-Carnitina<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">NAD\u207a<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Clase qu\u00edmica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Derivado de amino\u00e1cido con amonio cuaternario (zwitteri\u00f3n \u00fanico)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Coenzima dinucle\u00f3tido (adenina + nucle\u00f3tidos de nicotinamida unidos mediante difosfato)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">161,20 g\/mol<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">663.43 g\/mol<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Funci\u00f3n en las mitocondrias<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Transportador \u2014 lanzadera de \u00e1cidos grasos de cadena larga a trav\u00e9s de la membrana interna<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aceptor de electrones para la \u03b2-oxidaci\u00f3n, gluc\u00f3lisis, ciclo de Krebs; sustrato para sirtuinas y PARPs<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best-studied studies focus<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Oxidaci\u00f3n de grasas, sensibilidad a la insulina, cardiovascular, motilidad esperm\u00e1tica, fisiolog\u00eda del ejercicio<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Biolog\u00eda de las sirtuinas, longevidad, envejecimiento celular, regulaci\u00f3n redox del eje NAD<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Aprobaci\u00f3n de la FDA<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">S\u00ed \u2014 levocarnitina, para deficiencia primaria\/secundaria de carnitina (oral e intravenosa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">No \u2014 compound only<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Bios\u00edntesis end\u00f3gena<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">A partir de L-lisina y L-metionina, en ri\u00f1\u00f3n\/h\u00edgado\/cerebro<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">A partir de tript\u00f3fano (de novo) o nicotinamida\/niacina (reciclaje)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Estabilidad plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Estable \u2014 horas de vida media<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Inestable \u2014 vida media de pocos minutos en soluci\u00f3n; se oxida y degrada r\u00e1pidamente<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dosis t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Cientos de mg hasta nivel de gramos (dosis \u00fanica en protocolos con roedores\/grandes animales)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Decenas a cientos de mg (cultivo celular: concentraciones en \u00b5M)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on long-chain fatty-acid oxidation, cardiovascular metabolic function, insulin sensitivity, or sperm motility, L-Carnitine is the canonical reference compound. For studies focused on sirtuin biology, longevity-axis biochemistry, or NAD-dependent redox regulation, <a href=\"https:\/\/medsbase.com\/es\/nad\/\">NAD\u207a<\/a> es la herramienta m\u00e1s espec\u00edfica. V\u00e9ase tambi\u00e9n <a href=\"https:\/\/medsbase.com\/es\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> for cardiolipin \/ inner-membrane-targeted mitochondrial studies and <a href=\"https:\/\/medsbase.com\/es\/mots-c\/\">MOTS-c<\/a> for mitochondrial-derived peptide-signalling studies. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 \u00bfNecesitas agua BAC?<\/strong> La reconstituci\u00f3n de cualquier vial liofilizado requiere agua bacteriost\u00e1tica est\u00e9ril. Combina este producto con nuestro <a href=\"\/es\/bac-water\/\"><strong>Agua BAC (Agua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 vial multidosis de 30 mL, conservado con alcohol benc\u00edlico 0.9%, grado USP.<\/div>\n<h2>Almacenamiento y reconstituci\u00f3n<\/h2>\n<p><strong>Antes de la reconstituci\u00f3n:<\/strong> almacene los viales liofilizados refrigerados a 2\u20138 \u00b0C en su envase original para stock de trabajo a corto plazo. Para almacenamiento a largo plazo, congele los viales sin abrir a \u221220 \u00b0C. La L-Carnitina liofilizada es estable bajo refrigeraci\u00f3n hasta 36 meses y a \u221220 \u00b0C hasta 60 meses \u2014 sustancialmente m\u00e1s estable que la mayor\u00eda de los p\u00e9ptidos liofilizados debido a que la estructura de mol\u00e9cula peque\u00f1a no tiene enlaces amida ni puentes disulfuro que hidrolizar. Sin embargo, el compuesto es, <strong>higrosc\u00f3pico<\/strong>, por lo que vuelva a sellar los viales inmediatamente despu\u00e9s de cada extracci\u00f3n y evite la exposici\u00f3n prolongada a la humedad ambiental. <strong>Procedimiento de reconstituci\u00f3n:<\/strong> inyecte agua bacteriost\u00e1tica por la pared lateral del vial (no directamente sobre el polvo liofilizado). Para un vial de 600 mg, 3.0 mL de agua bacteriost\u00e1tica producen una concentraci\u00f3n de trabajo de 200 mg\/mL; 1.2 mL producen un stock de 500 mg\/mL. Para un vial de 1200 mg, 6.0 mL producen un stock de trabajo de 200 mg\/mL; 2.4 mL producen un stock de 500 mg\/mL. La L-Carnitina se disuelve muy r\u00e1pidamente con un suave giro \u2014 t\u00edpicamente en 10\u201330 segundos \u2014 porque es un peque\u00f1o zwitteri\u00f3n sin estructura plegada que perturbar. Una vez reconstituido, almacene el vial a 2\u20138 \u00b0C y \u00faselo dentro de los 30 d\u00edas. Prot\u00e9jalo de la luz. Des\u00e9chelo si aparece turbidez, part\u00edculas o cambio de color. <\/p>\n<h2>Preguntas frecuentes<\/h2>\n<h3>\u00bfEs la L-Carnitina un p\u00e9ptido?<\/h3>\n<p>No. La L-Carnitina es un derivado de amino\u00e1cido de amonio cuaternario de mol\u00e9cula peque\u00f1a (PM 161.20 g\/mol), <em>ajuste<\/em> a peptide. We stock it in our studies-peptide catalogue alongside <a href=\"https:\/\/medsbase.com\/es\/nad\/\">NAD\u207a<\/a> because it serves a complementary role in mitochondrial \/ metabolic support and is supplied in the same injectable vial format. The spec table Sequence row is marked &#8220;n\/a&#8221; for this reason. <\/p>\n<h3>\u00bfCu\u00e1l es la diferencia entre L-Carnitina y acetil-L-carnitina (ALCAR)?<\/h3>\n<p>Acetyl-L-carnitine is L-carnitine with an acetyl group esterified to the hydroxyl side chain. ALCAR crosses the blood-brain barrier more efficiently and is the form most commonly used in CNS-focused studies (Alzheimer-disease, peripheral neuropathy). The base L-carnitine zwitterion that we supply here is the form used in peripheral metabolic support (cardiovascular, skeletal muscle, sperm motility, dialysis-related deficiency). The two compounds interconvert metabolically through carnitine acetyltransferase. <\/p>\n<h3>\u00bfCu\u00e1l es la diferencia entre L-Carnitina y DL-carnitina rac\u00e9mica?<\/h3>\n<p>Only the L (3R) enantiomer is biologically active. The D (3S) enantiomer is inactive and is now well-documented to interfere with L-form transport, accumulating in tissue and producing weakness and other adverse effects in long-term high-dose contexts. Pharmaceutical-grade levocarnitine (what we supply) is the enantiomerically pure L-form. The racemic DL-form is obsolete and is no longer used in either clinical or rigorous contexts. <\/p>\n<h3>Why is the dose so much larger than the peptide doses in this catalogue?<\/h3>\n<p>L-Carnitine is a small molecule (MW 161) and is used at gram-level doses \u2014 the body&#8217;s endogenous carnitine pool is approximately 25 g, concentrated in skeletal muscle. Study protocols typically use 100\u2013500 mg\/kg in rodent in-vivo work, which translates to hundreds of milligrams to grams per dose. Compare this to peptides (BPC-157, semaglutide, etc.) where typical doses are 100 \u00b5g to 5 mg per administration \u2014 three to four orders of magnitude smaller, reflecting the different molecular weights and the different receptor \/ mechanism scales. <\/p>\n<h3>What is the TMA \/ TMAO question I see in cardiovascular studies?<\/h3>\n<p>A subset of L-carnitine ingested orally is degraded by gut bacteria to trimethylamine (TMA), which the liver then oxidises to trimethylamine-N-oxide (TMAO). Elevated TMAO levels have been associated in epidemiological studies with adverse cardiovascular events, raising a controversy about whether long-term high-dose oral L-carnitine supplementation may be net-beneficial or net-harmful for cardiovascular endpoints. The question is active and unresolved. Parenteral L-carnitine bypasses the gut-microbial degradation pathway and is not subject to this concern. <\/p>\n<h3>What does CPT-I inhibition mean in metabolic support?<\/h3>\n<p>Carnitine palmitoyltransferase I (CPT-I) is the rate-limiting enzyme for mitochondrial long-chain fatty-acid uptake. Etomoxir is a classical CPT-I inhibitor used to block fat oxidation in study models; it is the pharmacological tool counterpart to the L-carnitine substrate. Study protocols sometimes combine L-carnitine supplementation (substrate side) with CPT-I inhibition (enzymatic side) to dissect substrate-limited vs enzyme-limited fat oxidation in different tissues and conditions. <\/p>\n<h3>Can I combine L-Carnitine with NAD\u207a in the same protocol?<\/h3>\n<p>Yes \u2014 the two compounds target different layers of mitochondrial bioenergetics (substrate transport vs electron transport), and combination is commonly used in studies that aims to probe upstream vs downstream limitations on mitochondrial output. They are chemically stable in solution together. Reconstitute each separately first to establish stability and concentration accuracy, then combine immediately before use rather than co-storing reconstituted vials. <\/p>\n<h3>What route of administration is used in published studies?<\/h3>\n<p>Intravenous and intramuscular routes are most common in pharmacological studies because they bypass the low (~15%) oral bioavailability and the gut-microbial TMA\/TMAO degradation pathway. Subcutaneous administration is used in some rodent protocols. Oral administration is used in pharmacokinetic and nutritional studies where the bioavailability question is itself the studies focus. <!-- medsbase-related-alts-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Lanzadera mitocondrial de \u00e1cidos grasos de cadena larga (no es un p\u00e9ptido)<br \/>\n\u2705 Maquinaria de transporte CPT-I \/ CACT \/ CPT-II sustrato<br \/>\n\u2705 Estudiado en modelos de oxidaci\u00f3n de grasas, sensibilidad a la insulina y cardiovasculares<br \/>\n\u2705 Acyl-CoA \/ free-CoA ratio buffer; sperm-motility studies<br \/>\n\u2705 Levocarnitina aprobada por la FDA para deficiencia de carnitina (oral e intravenosa)<\/p>\n<p><strong>L-Carnitina<\/strong> contiene levocarnitina sint\u00e9tica.<\/p>","protected":false},"featured_media":71414,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6472,6469,6470,6471],"class_list":["post-71409","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-amino-acid-derivative","product_tag-l-carnitine","product_tag-levocarnitine","product_tag-mitochondrial","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product\/71409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/comments?post=71409"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media\/71414"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media?parent=71409"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_brand?post=71409"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_cat?post=71409"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_tag?post=71409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}